Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tretinoin + Zingiber officinale is an investigational combination therapy developed by Hasanuddin University for the treatment of mild to moderate acne vulgaris. The treatment regimen consists of a nightly application of tretinoin 0.025% cream followed by the application of a 5% Zingiber officinale (ginger) transdermal patch to specific pustules. Tretinoin is a small molecule retinoid that works by binding to retinoic acid receptors, normalizing epithelial desquamation, and reducing sebum production. Zingiber officinale extract provides complementary anti-inflammatory and antibacterial activities, specifically targeting interleukin-1 (IL-1) and modulating the skin microbiome to reduce acne lesions. This combination is currently being evaluated in a randomized, split-face clinical trial to assess its efficacy and safety compared to tretinoin monotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tretinoin + Zingiber officinale.